Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Colorectal cancer in 2014

Progress in defining first-line and maintenance therapies

Nature Reviews Clinical Oncology volume 12, pages 73–74 (2015)Cite this article

Subjects

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065–1075 (2014).

    Article  CAS  Google Scholar 

  2. Stintzing, S. et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population [abstract LBA11]. Ann. Oncol. 25 (Suppl. 5), v1–v41 (2014).

    Google Scholar 

  3. Venook, A. P. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), LBA3 (2014).

    Article  Google Scholar 

  4. Lenz, H. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC) [abstract]. Ann. Oncol. 25 (Suppl. 4), A5010 (2014).

    Google Scholar 

  5. Arnold, D. et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), 3503 (2014).

    Article  Google Scholar 

  6. Chibaudel, B. et al. Bevacizumab-erlotinib as maintenance therapy in metastatic colorectal cancer. Final results of the GERCOR DREAM study [abstract 4970]. Ann. Oncol. 25 (Suppl. 4), iv167–iv209 (2014).

    Article  Google Scholar 

  7. Koopman, M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) [abstract]. J. Clin. Oncol. 32 (Suppl. 3), LBA388 (2014).

    Article  Google Scholar 

  8. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303–312 (2013).

    Article  CAS  Google Scholar 

  9. Kim, T. W. et al. CONCUR: a randomized, placebo-controlled phase 3 study of regorafenib (REG) monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC) [abstract 500O]. Ann. Oncol. 25 (Suppl. 4), iv168–iv169 (2014).

    Article  Google Scholar 

  10. Van Cutsem, E. et al. Phase III RECOURSE trial of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies [abstract LBA13]. Ann. Oncol. 25 (Suppl. 5), v1–v41 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, USA

    Joleen M. Hubbard & Axel Grothey

Authors
  1. Joleen M. Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Grothey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Grothey.

Ethics declarations

Competing interests

Research funding for A.G. was provided by Bayer, Eisai/Morphotek, Eli–Lilly, Genentech, Pfizer, and Sanofi. A.G. received honoraria for consulting from Amgen, Bayer, Boston Biomedicals, Bristol–Myers Squibb, Eli-Lilly, Genentech/Roche, and Sanofi. Research funding for J.M.H. was provided by Boston Biomedicals, Genentech and, PRISM. The Mayo Clinic Foundation received honoraria for consulting by J.M.H from Bayer.

Supplementary information

Supplementary Table 1

Comparison of outcomes of FIRE 3 and CALGB/SWOG 80405 trials (DOC 52 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hubbard, J., Grothey, A. Progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol 12, 73–74 (2015). https://doi.org/10.1038/nrclinonc.2014.233

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.233

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing